Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02964325
Previous Study | Return to List | Next Study

Efficacy of Mirasol-treated Apheresis Platelets in Patients With Hypoproliferative Thrombocytopenia (MIPLATE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02964325
Recruitment Status : Terminated (Based interim analysis results, Data Monitoring Committee did not believe the primary efficacy endpoint would be met. No patient safety concerns.)
First Posted : November 16, 2016
Results First Posted : July 16, 2021
Last Update Posted : July 16, 2021
Sponsor:
Collaborator:
Biomedical Advanced Research and Development Authority
Information provided by (Responsible Party):
Terumo BCTbio

Brief Summary:
This is a prospective, multi-center, controlled, randomized, non-inferiority study to evaluate the clinical effectiveness of Conventional versus Mirasol-treated apheresis platelets in subjects with hypoproliferative thrombocytopenia who are expected to have platelet count(s) ≤ 10,000/μL requiring ≥ 2 platelet transfusions.

Condition or disease Intervention/treatment Phase
Hematologic Malignancies Hypoproliferative Thrombocytopenia Device: Mirasol platelets (MIR PLTs) Device: Reference platelets (REF PLTs) Not Applicable

Detailed Description:

Patients will be randomized 1:1 to Mirasol-treated platelets (test platelets) or to conventional, untreated platelets (control platelets). The blood centers will collect the apheresis donor platelets and supply the test platelets to the hospital sites for transfusion into patients. Hospital sites will order control platelets as per their normal process, from their standard vendor.

The target population for the MIPLATE study are patients with hematologic malignancies with hypoproliferative thrombocytopenia who are expected to have platelet (PLT) count(s) of ≤ 10,000/μL requiring ≥ 2 PLT transfusions.

The primary objective of MIPLATE is to determine if the hemostatic efficacy of Mirasol-treated plasma stored Trima Accel® Aph PLTs are non-inferior to Conventional plasma stored Aph PLTs in subjects with hypoproliferative thrombocytopenia requiring PLT transfusions. The secondary objectives include comparing other efficacy and safety endpoints between the treatment groups.

Subjects with hematologic malignancies with hypoproliferative thrombocytopenia are anticipated to experience a "transfusion episode" where they will require PLT transfusion support until bone marrow recovery. During this period all PLT transfusions required for a study subject will be given according to the subject's treatment allocation for 28 days after the initial PLT transfusion OR until transfusion independence (10 days without PLT transfusion) prior to Day 28.

Additionally, serum samples for HLA antibody testing will be collected on Days 14, 28 and 56.

At a minimum, the initial post-randomization prophylactic PLT transfusion will be initiated for a PLT count ≤ 10,000/µL. Thereafter, indications for PLT transfusions may be PLT count-related prophylaxis, intervention-related prophylaxis, or therapeutic (treatment of active bleeding) as determined by the treating physician(s). The indication(s) for the transfusion(s) will be captured.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 422 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Investigator, Outcomes Assessor)
Masking Description: Though this is not a blinded study, treatment assignment is obtained through electronic system and should not be shared those performing the primary outcome assessment or assessors of adverse events.
Primary Purpose: Supportive Care
Official Title: Clinical Effectiveness of Conventional Versus Mirasol-treated Apheresis Platelets in Patients With Hypoproliferative Thrombocytopenia
Actual Study Start Date : May 5, 2017
Actual Primary Completion Date : June 25, 2020
Actual Study Completion Date : June 25, 2020

Arm Intervention/treatment
Experimental: Mirasol platelets (MIR PLTs)
Leukoreduced, Trima Accel® apheresis platelets stored in 100% plasma, pathogen reduced with the Mirasol® Pathogen Reduction Technology (PRT) System
Device: Mirasol platelets (MIR PLTs)
The final product to be transfused to the subject will be leukoreduced (LR), apheresis (Aph) single-donor platelets (PLTs) at the standard therapeutic dose of 1 unit of Aph PLTs containing ≥ 3.0 × 1.0E11 PLTs. MIR PLTs will be treated with the Mirasol pathogen reduction technology system.

Active Comparator: Reference platelets (REF PLTs)
Leukoreduced, apheresis platelets stored in 100% plasma
Device: Reference platelets (REF PLTs)
The final product to be transfused to the subject will be LR-Aph single-donor PLTs at the standard therapeutic dose of 1 unit of Aph PLTs containing ≥ 3.0 × 1.0E11 PLTs.




Primary Outcome Measures :
  1. Days of ≥ Grade 2 Bleeding [ Time Frame: From the first post-randomization platelet transfusion through 28 days following the first transfusion. ]
    Number of days of Grade 2 or higher bleeding recorded from treatment start date through 28 days following the first transfusion, until transfusion independence (10 days without PLT transfusion) prior to Day 28, or study termination, whichever occurred first. Subjects who obtained transfusion independence prior to Day 28 were assumed to have zero bleeding events between the date of transfusion independence and Day 28. Observed and simulated data for off-protocol transfusion intervals were included.


Secondary Outcome Measures :
  1. Human Leukocyte Antigen (HLA) Alloimmunization [ Time Frame: HLA antibodies were measured at Baseline and Days 14, 28, and 56. ]
    The outcome was the development of a new HLA Class I antibodies among subjects negative at Baseline within each treatment group. Positivity for Class I HLA antibodies was determined by the 5 SD normalized background ratio cutoffs assay threshold (>59.2, LABScreen Mixed LSM12, One Lambda).

  2. Proportion of Subjects With ≥ Grade 2 Bleeding [ Time Frame: From the first post-randomization platelet transfusion through 28 days following the first transfusion. ]
    The proportion of subjects with at least 1 day of ≥ Grade 2 bleeding from Day 0 through Day 27 (or until transfusion independence was achieved) by treatment group

  3. Time to First ≥ Grade 2 Bleed [ Time Frame: From the first post-randomization platelet transfusion through 28 days following the first transfusion. ]
    The time to first ≥ Grade 2 bleeding was analyzed using a log-rank test comparing survival curves stratified by treatment group.

  4. Proportion of Subjects With ≥ Grade 3 Bleeding [ Time Frame: From the first post-randomization platelet transfusion through 28 days following the first transfusion. ]
    The proportion of subjects with at least 1 day of ≥ Grade 3 bleeding from Day 0 through Day 27 (or until transfusion independence was achieved).

  5. Proportion of Subjects With PLT Refractoriness [ Time Frame: From the first post-randomization platelet transfusion through 28 days following the first transfusion. ]
    Proportion of subjects with PLT refractoriness defined as 2 sequential transfusions, each with corrected count increments (CCIs) < 5000 measured 1 hour post-transfusion.

  6. Proportion of Subjects With Immune Platelet Refractoriness [ Time Frame: Initial post-randomization platelet transfusion through high Class I HLA development. ]
    The proportion of subjects with PLT refractoriness for each treatment group. Subjects were defined as immune PLT refractoriness based on 2 sequential transfusion episodes, each with CCIs < 5000 measured 1 hour post transfusion, and who also had a positive antibody test within 14 days before or after the onset of PLT refractoriness.


Other Outcome Measures:
  1. Unanticipated Adverse Device Effects (UADEs) [ Time Frame: From initial post-randomization PLT transfusion through 72 hours following the last per protocol PLT transfusion. ]
    UADEs are identified as treatment emergent adverse events reported by the investigator as serious, unanticipated, at least possibly related to study device or at least possibly related to treatment. UADEs were coded using Medical Dictionary for Regulatory Activities (MedDRA) Version 19.1



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Weight > 10 kg (22 lbs)
  2. Subject has a hematologic malignancy with hypoproliferative thrombocytopenia and is expected to have PLT count(s) ≤ 10,000/µL requiring ≥ 2 PLT transfusions
  3. Laboratory results within 5 days prior to anticipated initiation of the first post randomization PLT transfusion:

    1. Prothrombin time (PT) and/or international normalized ratio (INR) ≤ 1.3 × the upper limit of normal (ULN)
    2. Activated partial thromboplastin time (aPTT) ≤ 1.3 × ULN
    3. Fibrinogen ≥ 100 mg/dL
  4. Women of childbearing potential must have a negative pregnancy test and agree to practice a medically acceptable contraception regimen for the study duration. Women who are postmenopausal for at least 1 year (> 12 months since last menses) or are surgically sterilized do not require this test
  5. IC from the subject or assent from the subject and consent from a parent or guardian, if the subject is < 18 years of age

Exclusion Criteria:

  1. Treatment with pathogen-reduced blood products within previous 6 months
  2. Subject has been previously enrolled in this study and received at least 1 per protocol PLT transfusion
  3. a.) Subject is receiving therapeutic doses of antiplatelet agents, antifibrinolytics, and/or PLT specific growth factors within 10 days prior to randomization or b.) Subject is receiving therapeutic doses of anticoagulant, pro-coagulant or antithrombotic agents within 10 days prior to randomization. Subjects can be included if receiving the following: prophylactic dosing of anticoagulants (heparin, any low molecular weight heparin, enoxaparin, or fondaparinux), anticoagulants/thrombolytic agents used to maintain or re-establish the patency of catheters (heparin flushes or tissue-plasminogen activase [TPA], therapeutic doses of anticoagulants with a half-life of < 24 hours if it will be discontinued at least 24 hours prior to the first study transfusion, single periprocedural doses of anticoagulants with a half-life of < 24 hours or low dose aspirin (81 mg per day)
  4. Subject has ≥ grade 2 bleeding at the time of randomization
  5. Planned administration of bedside LR PLT transfusion(s)
  6. Presently with or a history of acute promyelocytic leukemia (APML), idiopathic thrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), or hemolytic uremic syndrome (HUS)
  7. HLA and/or HPA-alloimmunization and/or platelet refractory as determined by the investigator
  8. Hypersplenism as evidenced by splenomegaly based on investigator assessment at baseline
  9. History or diagnosis of a disease affecting hemostasis
  10. Currently taking, or participating in a clinical study involving PLT substitutes, PLT growth factors, or pharmacologic agents intended to enhance (i.e, antifibrinolytic agents) or decrease PLT hemostatic function
  11. Acute or chronic medical disorder that, in the opinion of the investigator, would impair the ability of the subject to receive protocol treatment
  12. Subject is pregnant or lactating
  13. Inability of the subject to comply with study procedures and/or follow-up

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02964325


Locations
Layout table for location information
United States, District of Columbia
Children's National Medical Center
Washington, District of Columbia, United States, 20010
United States, Florida
University of Florida Health Shands Hospital
Gainesville, Florida, United States, 32608
United States, Georgia
Emory University/Children's Hospital of Atlanta
Atlanta, Georgia, United States, 30322
United States, Iowa
University of Iowa
Iowa City, Iowa, United States, 52242
United States, Maryland
John Hopkins University School of Medicine/Johns Hopkins Kimmel Cancer Center
Baltimore, Maryland, United States, 21231
United States, Massachusetts
Boston Children's Hospital
Boston, Massachusetts, United States, 02115
United States, Missouri
Washington University in St. Louis
Saint Louis, Missouri, United States, 63110
United States, Nebraska
University of Nebraska Medical Center
Omaha, Nebraska, United States, 68198
United States, New Jersey
Robert Wood Johnson Medical School/RWJ University Hospital
New Brunswick, New Jersey, United States, 08903
United States, Washington
University of Washington Medical Center
Seattle, Washington, United States, 98109
Sponsors and Collaborators
Terumo BCTbio
Biomedical Advanced Research and Development Authority
Investigators
Layout table for investigator information
Study Director: Robert Cortes, MD Terumo BCT
Principal Investigator: Sherrill Slichter, MD Bloodworks Northwest
  Study Documents (Full-Text)

Documents provided by Terumo BCTbio:
Study Protocol  [PDF] January 30, 2019
Statistical Analysis Plan  [PDF] September 2, 2020

Layout table for additonal information
Responsible Party: Terumo BCTbio
ClinicalTrials.gov Identifier: NCT02964325    
Other Study ID Numbers: CTS-5030
First Posted: November 16, 2016    Key Record Dates
Results First Posted: July 16, 2021
Last Update Posted: July 16, 2021
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Keywords provided by Terumo BCTbio:
hypoproliferative thrombocytopenia
hematologic malignancies
thrombocytopenia
platelet therapy
apheresis
pathogen reduction therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Hematologic Neoplasms
Thrombocytopenia
Blood Platelet Disorders
Hematologic Diseases
Neoplasms by Site